Memory T Cells pp 155-165 | Cite as

Antigen Specific Memory T Cells and Their Putative Need for the Generation of Sustained Anti-Tumor Responses

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 684)


Memory T-cell responses to cancer antigens may be an effective way to sustain long-term tumor-free survival. However, finding an effective vaccination strategy to induce memory T-cell responses toward tumor associated antigens in patients with existing disease has proven to be extremely difficult. Immune stimulation regimens have been combined with tumor vaccination in an attempt to boost the immune response resulting in better vaccine efficacy. In these instances immune stimulation alone has shown some promise as a primary tumor therapy, but has been less effective at eliciting long-term tumor immunity. Likewise, combining systemic adjuvant therapy with tumor antigen vaccination also demonstrated a lack of sustained anti-tumor immunity in cancer patients. In this review, we discuss whether the immune response generated during immune stimulation is appropriate for supporting memory T-cell generation or whether initial tumor regression and generation of sustained anti-tumor immunity have different immunological signaling requirements.


Human Papilloma Virus Tumor Associate Antigen Cancer Antigen Central Memory Immune Stimulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weinberg RA. The Biology of Cancer 1st ed. New York: Garland Science, Taylor and Francis Group; 2007.Google Scholar
  2. 2.
    Minev BR, Chavez FL, Mitchell MS. Cancer vaccines: novel approaches and new promise. Pharmacol Ther 1999; 81:121–139.PubMedCrossRefGoogle Scholar
  3. 3.
    Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine 2007; 25 (Suppl 2) B72–88.PubMedCrossRefGoogle Scholar
  4. 4.
    Govan VA. A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). Ther Clin Risk Manag 2008; 4:65–70.PubMedGoogle Scholar
  5. 5.
    Muderspach L, Wilczynski S, Roman L et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6:3406–3416.PubMedGoogle Scholar
  6. 6.
    Poolman EM, Elbasha EH, Galvani AP. Vaccination and the evolutionary ecology of human papillomavirus. Vaccine 2008; 26 Suppl 3:C25–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225–274.PubMedCrossRefGoogle Scholar
  8. 8.
    Sheu BC, Lin RH, Lien HC et al. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 2001; 167:2972–2978.PubMedGoogle Scholar
  9. 9.
    Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007; 16:755–774, viii.PubMedCrossRefGoogle Scholar
  10. 10.
    Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007; 13:5256–5261.PubMedCrossRefGoogle Scholar
  11. 11.
    Simpson-Abelson M, Bankert RB. Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T-cells in the tumor microenvironment. Expert Opin Ther Targets 2008; 12:477–490.PubMedCrossRefGoogle Scholar
  12. 12.
    Porta C, Subhra Kumar B, Larghi P et al. Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol 2007; 604:67–86.PubMedCrossRefGoogle Scholar
  13. 13.
    Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8:467–477.PubMedCrossRefGoogle Scholar
  14. 14.
    Koyama S, Koike N, Adachi S. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol 2002; 128:73–79.PubMedCrossRefGoogle Scholar
  15. 15.
    Lopez-Gonzalez JS, Hernandez Garcia A, Noyola MI et al. Evasion mechanisms to tumor necrosis factor alpha (TNF-alpha) of small cell lung carcinoma and nonsmall cell lung carcinoma cell lines: comparison with the erythroleukaemia K-562 cell line. Lung Cancer 2000; 27:177–187.PubMedCrossRefGoogle Scholar
  16. 16.
    Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008; 68:2561–2563.PubMedCrossRefGoogle Scholar
  17. 17.
    Savage PA, Vosseller K, Kang C et al. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T-lymphocytes. Science 2008; 319:215–220.PubMedCrossRefGoogle Scholar
  18. 18.
    Eerola AK, Soini Y, Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 2000; 6:1875–1881.PubMedGoogle Scholar
  19. 19.
    Parshad R, Hazrah P, Kumar S et al. Effect of preoperative short course famotidine on TILs and survival in breast cancer. Indian J Cancer 2005; 42:185–190.PubMedGoogle Scholar
  20. 20.
    Liakou CI, Narayanan S, Ng Tang D et al. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 2007; 7:10.PubMedGoogle Scholar
  21. 21.
    Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007; 7:4.PubMedGoogle Scholar
  22. 22.
    Dunn GP, Dunn IF, Curry WT. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 2007; 7:12.PubMedGoogle Scholar
  23. 23.
    Holmes EC. Immunology of tumor infiltrating lymphocytes. Ann Surg 1985; 201:158–163.PubMedCrossRefGoogle Scholar
  24. 24.
    Blohm U, Roth E, Brommer K et al. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J Immunol 2002; 169:5522–5530.PubMedGoogle Scholar
  25. 25.
    Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850–854.PubMedCrossRefGoogle Scholar
  26. 26.
    Koebel CM, Vermi W, Swann JB et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903–907.PubMedCrossRefGoogle Scholar
  27. 27.
    Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329–360.PubMedCrossRefGoogle Scholar
  28. 28.
    Berner V, Liu H, Zhou Q et al. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 2007; 13:354–360.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhang B, Bowerman NA, Salama JK et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T-cells. J Exp Med 2007; 204:49–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Zhang B, Zhang Y, Bowerman NA et al. Equilibrium between host and cancer caused by effector T-cells killing tumor stroma. Cancer Res 2008; 68:1563–1571.PubMedCrossRefGoogle Scholar
  31. 31.
    Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines 2008; 7:467–479.PubMedCrossRefGoogle Scholar
  32. 32.
    Chambers SM, Goodell MA. Hematopoietic stem cell aging: wrinkles in stem cell potential. Stem Cell Rev 2007; 3:201–211.PubMedCrossRefGoogle Scholar
  33. 33.
    Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology 2007; 120:435–446.PubMedCrossRefGoogle Scholar
  34. 34.
    Pugliese A. Central and peripheral autoantigen presentation in immune tolerance. Immunology 2004; 111:138–146.PubMedCrossRefGoogle Scholar
  35. 35.
    Keir ME, Liang SC, Guleria I et al. Tissue expression of PD-L1 mediates peripheral T-cell tolerance. J Exp Med 2006; 203:883–895.PubMedCrossRefGoogle Scholar
  36. 36.
    Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027–1034.PubMedCrossRefGoogle Scholar
  37. 37.
    Goldberg MV, Maris CH, Hipkiss EL et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T-cells. Blood 2007; 110:186–192.PubMedCrossRefGoogle Scholar
  38. 38.
    Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793–800.PubMedGoogle Scholar
  39. 39.
    Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994; 12:991–1045.PubMedGoogle Scholar
  40. 40.
    Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T-cell responses to vaccination with peptide, IFA and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115:739–746.PubMedGoogle Scholar
  41. 41.
    Anderson TD, Hayes TJ, Powers GD et al. Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals. Int Rev Exp Pathol 1993; 34 Pt A:57–77.PubMedGoogle Scholar
  42. 42.
    Dutcher J, Atkins MB, Margolin K et al. Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol 2001; 18:209–219.PubMedCrossRefGoogle Scholar
  43. 43.
    Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321–327.PubMedCrossRefGoogle Scholar
  44. 44.
    Escobar A, Lopez M, Serrano A et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005; 142:555–568.PubMedGoogle Scholar
  45. 45.
    Harthun NL, Weaver AM, Brinckerhoff LH et al. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2. J Immunother 1998; 21:85–94.PubMedCrossRefGoogle Scholar
  46. 46.
    Roberts JD, Niedzwiecki D, Carson WE et al. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother 2006; 29:95–101.PubMedCrossRefGoogle Scholar
  47. 47.
    Lindsey KR, Gritz L, Sherry R et al. Evaluation of prime/boost regimens using recombinant poxvirus/ tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res 2006; 12:2526–2537.PubMedCrossRefGoogle Scholar
  48. 48.
    Sallusto F, Lanzavecchia A. Exploring pathways for memory T-cell generation. J Clin Invest 2001; 108:805–806.PubMedGoogle Scholar
  49. 49.
    Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T-cell subsets: function, generation and maintenance. Annu Rev Immunol 2004; 22:745–763.PubMedCrossRefGoogle Scholar
  50. 50.
    Sprent J, Surh CD. T-cell memory. Annu Rev Immunol 2002; 20:551–579.PubMedCrossRefGoogle Scholar
  51. 51.
    Surh CD, Boyman O, Purton JF et al. Homeostasis of memory T-cells. Immunol Rev 2006; 211:154–163.PubMedCrossRefGoogle Scholar
  52. 52.
    Suresh M, Whitmire JK, Harrington LE et al. Role of CD28-B7 interactions in generation and maintenance of CD8 T-cell memory. J Immunol 2001; 167:5565–5573.PubMedGoogle Scholar
  53. 53.
    Vallejo AN. CD28 extinction in human T-cells: altered functions and the program of T-cell senescence. Immunol Rev 2005; 205:158–169.PubMedCrossRefGoogle Scholar
  54. 54.
    Perez-Diez A, Joncker NT, Choi K et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109:5346–5354.PubMedCrossRefGoogle Scholar
  55. 55.
    Badovinac VP, Messingham KA, Griffith TS et al. TRAIL deficiency delays, but does not prevent, erosion in the quality of “helpless” memory CD8 T-cells. J Immunol 2006; 177:999–1006.PubMedGoogle Scholar
  56. 56.
    Sun JC, Williams MA, Bevan MJ. CD4+ T-cells are required for the maintenance, not programming, of memory CD8+ T-cells after acute infection. Nat Immunol 2004; 5:927–933.PubMedCrossRefGoogle Scholar
  57. 57.
    Prlic M, Williams MA, Bevan MJ. Requirements for CD8 T-cell priming, memory generation and maintenance. Curr Opin Immunol 2007; 19:315–319.PubMedCrossRefGoogle Scholar
  58. 58.
    Janssen EM, Droin NM, Lemmens EE et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005; 434:88–93.PubMedCrossRefGoogle Scholar
  59. 59.
    Janssen EM, Lemmens EE, Wolfe T et al. CD4+ T-cells are required for secondary expansion and memory in CD8+ T-lymphocytes. Nature 2003; 421:852–856.PubMedCrossRefGoogle Scholar
  60. 60.
    Alderson KL, Zhou Q, Berner V et al. Regulatory and conventional CD4+ T-Cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy. J Immunol 2008; 180:2981–2988.PubMedGoogle Scholar
  61. 61.
    Murphy WJ, Welniak L, Back T et al. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol 2003; 170:2727–2733.PubMedGoogle Scholar
  62. 62.
    Bartholdy C, Kauffmann SO, Christensen JP et al. Agonistic anti-CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus. J Immunol 2007; 178:1662–1670.PubMedGoogle Scholar
  63. 63.
    Verneris MR, Karami M, Baker J et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T-cells. Blood 2004; 103:3065–3072.PubMedCrossRefGoogle Scholar
  64. 64.
    Wen H, Dou Y, Hogaboam CM et al. Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood 2008; 111:1797–1804.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  1. 1.University of CaliforniaDavisUSA

Personalised recommendations